ANN ARBOR – Early drug development is a key time in the life of a potential new drug. Decisions and strategy employed at this early stage can affect later development and even registration of a new product. Join MichBio May 27 for a webinar that presents some basic information regarding key decisions and challenges faced in early drug development.
In this webinar Ross Lobell, Principal Consultant at RegSource Consulting Inc., will show how regulatory professionals can be an important ally in arriving at the best strategy for a given molecule. It is hoped that the listener will gain an appreciation for some of the complexities of the strategic process that is relevant to modern drug development for both small and large molecules.
Lobell has been in the pharma/biopharma business for over 30 years having worked at Schering-Plough, Pfizer, Amgen, and most recently MedImmune/Astra-Zeneca. He has had regulatory responsibilities for a variety of therapeutic areas including oncology, pulmonary, auto-immunity, lipid metabolism, and virology and has participated in drug development throughout all stages, including NDA/BLA submissions.
Non-member cost: $25
MichBio U is generously sponsored by Bank of America Merrill Lynch.
Tuesday, May 27
10 a.m. – 11 a.m.
To register, click on MichBio.Org
